Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MAP3
MAP3 Details
Status: Closed 
Activation Date: 2004FEB11
Closing Date: 2010MAR23
Phase: III 

Description: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer 

Eligibility: Postmenopausal women at increased risk for the development of breast cancer are eligible for this study 

Objective: To determine if exemestane reduces the incidence of invasive breast cancer compared with placebo 

Participation: Open to member centres 

Lay Description: After menopause when the ovaries stop making estrogen the body continues to make estrogen from skin, muscle and fat. Even though it is only present at low levels it continues to be very important in the development of breast cancer. A new drug, called exemestane, stops the supply of estrogen to pre-cancerous and cancerous cells and helps to prevent them from growing.  

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
BREAST MAP3 4560 31 82 89
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
BREAST MAP3 4560 1 1
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
BREAST MAP3 4560 4143 0 547 0 5 4330 0 0